• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Home-Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021-2022-A Pilot St

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2024 Dec;18(12):e70034.
doi: 10.1111/irv.70034. Home-Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021-2022-A Pilot Study

Jocelyn Moyes[SUP] 1 [/SUP], Mvuyo Makhazi[SUP] 1 2 [/SUP], Sibongile Walaza[SUP] 1 2 [/SUP], Phiwokuhle Ntombela[SUP] 1 [/SUP], Fahima Moosa[SUP] 1 [/SUP], Anne von Gottberg[SUP] 1 3 [/SUP], Nicole Wolter[SUP] 1 3 [/SUP], Mignon du Plessis[SUP] 1 [/SUP], Gillian Hunt[SUP] 4 [/SUP], Cherie Cawood[SUP] 5 [/SUP], Erica Dueger[SUP] 6 [/SUP], Cheryl Cohen[SUP] 1 2 [/SUP]



Affiliations
Abstract

Background: Surveillance programmes for influenza and other respiratory pathogens are important to generate vaccine effectiveness (VE) estimates and to inform vaccine composition. We aimed to explore the feasibility and acceptability of home-based testing.
Methods: In three out of nine provinces in South Africa, we established a self-referral system for individuals aged ≥ 18 years with respiratory symptoms of ≤ 10 days duration. Following consent, swab collection material was delivered to participants who also completed a questionnaire including self-reported vaccination status. Swabs were tested by PCR for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. A test-negative methodology was used to estimate influenza VE.
Results: Of 1456 samples collected between 19 November 2021 and 3 September 2022, 73 (5%) tested positive for influenza, 38 (3%) tested positive for RSV and 394 (27%) for SARS-CoV-2. We subtyped 55% (40/73) of the influenza positive specimens; 16/40 (40%) were influenza A(H1N1)pdm09; 10/40 (25%)A(H3N2)) and all 14/40(35%) influenza B were B/Victoria. Only 20% (279/1451) of participants reported influenza-like illness case definition symptoms of fever and cough. Influenza vaccine coverage was 11% (157/1454). The overall influenza VE was 26% (95% confidence interval: -73%, 69%). Of the completed acceptability questionnaires, 123/127 (97%) participants would make use of the service again; 90% (1306) were recruited via the COVID-19 testing centre (call in, social media, webpage), and 7% (99/1306) through CoughWatchSA.
Conclusions: Home-based swabbing was feasible and acceptable. We were able to calculate an influenza VE, although a larger sample size and verification of vaccine status may improve the VE estimates in the future.

Keywords: home‐based self swabbing; influenza; influenza vaccine effectiveness.

 
Back
Top Bottom